Illinois Sports Medicine and Orthopaedic Centers
- PRP Therapy
- Laser Therapy (LLLT)
- Arthritis Treatment
- Stem Cell Therapy
Glenview, IL
Glenview supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through NorthShore Glenbrook Hospital and nearby Northwestern Medicine, and stem cell practice in the area spans Willow Road, The Glen, and neighboring Northbrook. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Illinois regulates physician practice through the Department of Financial and Professional Regulation. There is no Illinois-specific stem cell disclosure statute, so federal 21 CFR Part 1271 rules apply. The FDA has issued warning letters to Illinois stem cell operators for unapproved biologics. The 5 Glenview clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Illinois DFPR licensure checks.
Regulatory context
Illinois cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Illinois for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Chicago's medical research density also includes legitimate IND-based trials at academic institutions.
The FDA has issued warning letters to Illinois clinics offering stem cell, exosome, and umbilical cord-derived therapies. The Illinois Department of Financial and Professional Regulation has disciplined physicians for unprofessional conduct related to regenerative medicine. The Illinois Attorney General has used the Consumer Fraud and Deceptive Business Practices Act to pursue clinics making unsupported clinical claims, including class-action partnerships with private plaintiffs. Chicago's market draws ongoing federal attention. No statewide injunction parallel to the California SVF case has been issued, but enforcement risk remains material.